首页> 外国专利> USE OF A SEXUAL STEROID PRECURSOR SELECTED FROM THE GROUP THAT CONSISTS OF DEHYDROEPIANDROSTERONE, DEHYDROEPIANDROSTERONE SULFATE, ANDROST-5-ENO-3?, 17? -DIOL AND 4-ANDROSTEN-3,17-DIONA, use of this reference WITH A SELECTIVE STROGEN RECEPTOR MODULATOR FOR UTERINE AND BREAST CANCER PROTECTION AGAINST CANCER, PHARMACEUTICAL COMPOSITION AND KIT

USE OF A SEXUAL STEROID PRECURSOR SELECTED FROM THE GROUP THAT CONSISTS OF DEHYDROEPIANDROSTERONE, DEHYDROEPIANDROSTERONE SULFATE, ANDROST-5-ENO-3?, 17? -DIOL AND 4-ANDROSTEN-3,17-DIONA, use of this reference WITH A SELECTIVE STROGEN RECEPTOR MODULATOR FOR UTERINE AND BREAST CANCER PROTECTION AGAINST CANCER, PHARMACEUTICAL COMPOSITION AND KIT

机译：选自由以下物质组成的组的性甾体前体的组成：去氢表雄酮，硫酸去甲表雄酮和ANDROST-5-ENO-3？，17？ -DIOL和4-ANDROSTEN-3,17-DIONA，此参考文献与选择性雌激素受体调节剂一起用于子宫和乳腺癌的抗癌，药物成分和试剂盒

页面导航

摘要
著录项
相似文献

摘要

sex steroid precursors alone or in combination with a selective estrogen receptor modulator and / or with estrogens and / or type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women. new methods for treating or reducing the likelihood of acquiring vaginal dysfunction, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving the administration of a sexual steroid precursor . the additional administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of raloxifene, arzoxifene, tamoxifen, droloxifene, toremifene, iodoxifene, gw 5638, tse-424, era-923 and lasofoxifene, and more particularly compounds that have the general structure are specifically revealed for medical treatment and / or inhibiting the development of some of the diseases mentioned above. pharmaceutical compositions for releasing active ingredient (s) and kit (s) useful for the invention are also disclosed.

机译：性类固醇前体单独使用或与选择性雌激素受体调节剂和/或与雌激素和/或5型cgmp磷酸二酯酶抑制剂联合使用，可预防和治疗绝经后妇女的阴道干燥和性功能障碍。在包括人类在内的易感温血动物（包括使用性类固醇前体）的治疗中，治疗或减少获得阴道功能障碍，尤其是阴道干燥和性交困难，导致性功能障碍以及低性欲和性行为的可能性的新方法。额外给予雌激素或选择性雌激素受体调节剂，特别是选自雷洛昔芬，阿佐昔芬，他莫昔芬，屈洛昔芬，托瑞米芬，碘多芬，gw 5638，tse-424，era-923和拉索昔芬的化合物，更特别是具有明确揭示了其总体结构，以用于医学治疗和/或抑制上述某些疾病的发展。还公开了用于本发明的释放活性成分的药物组合物和试剂盒。

著录项

公开/公告号BRPI0516243B1

专利类型
公开/公告日2020-08-11

原文格式PDF
申请/专利权人 ENDORECHERCHE INC.;
展开▼

申请/专利号BR2005PI16243
发明设计人 FERNAND LABRIE;LOUISE BERGER;MOHAMED EL-ALFY;
展开▼

申请日2005-10-20
分类号A61K31/453;A61K31/519;A61K31/566;A61K31/5685;A61P15/02;
国家 BR
入库时间 2022-08-21 11:18:11

相似文献

专利
外文文献
中文文献